# A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

> **NCT04121221** · PHASE3 · COMPLETED · sponsor: **Mapi Pharma Ltd.** · enrollment: 1016 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** GA Depot
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04121221
- **Lead sponsor:** Mapi Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-19
- **Primary completion:** 2023-06-13
- **Final completion:** 2023-06-13
- **Target enrollment:** 1016 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121221, "A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04121221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*